-
A large number of drugs for the treatment of advanced solid tumors have been approved for clinical use, involving Hengrui, Henlius, etc.
Time of Update: 2022-04-15
HLX301 Fosun Pharma announced that recently, the application for clinical trials of HLX301 (recombinant human anti-PD-L1 and anti-TIGIT bispecific antibody injection) of Henlius, a holding subsidiary of the company, for the treatment of advanced tumors has been approved by the State Food and Drug Administration.
-
In March, 86 new varieties passed the consistency evaluation, and this pharmaceutical company has 5 varieties that have passed the evaluation.
Time of Update: 2022-04-15
In March, 5 varieties have passed the consistency evaluation, including salbutamol desulfate injection, dexamethasone sodium phosphate injection, lidocaine hydrochloride injection, Laxole sustained-release tablets, etc.
com, the market size of terminal salbutamol in China's public medical institutions has exceeded 1 billion yuan in 2020, of which injection sales accounted for about 21% .
-
The 3rd CBIC Cell Bio-Industry Conference and Biomedicine Conference
Time of Update: 2022-04-15
[Pharmaceutical Network Conference Forum] The biopharmaceutical industry is one of the key strategic emerging industries in China. At present, China is in an important stage of strategic transformat
-
In the first quarter of 2022, companies in the field of biological products performed well
Time of Update: 2022-04-15
For example, Tonghua Dongbao, an "insulin leader", expects to achieve a net profit of 817 million yuan attributable to shareholders of listed companies in the first quarter of 2022, an increase of 480 million yuan over the same period last year, or an increase of about 142.
-
From January to March 2022, CDE will undertake to accept 18 new Chinese medicine registration applications
Time of Update: 2022-04-15
From January to March 2022, the company has received a total of 5 new Chinese medicine registration applications, including 2.
This is also the first innovative traditional Chinese medicine drug approved for marketing in China this year .
-
Under the normalization of centralized procurement, a large number of pharmaceutical companies have accelerated the consistency evaluation!
Time of Update: 2022-04-15
Tianyao announced on the evening of March 22 that the dexamethasone sodium phosphate injection of its subsidiary Jinyao Pharmaceutical passed the quality and efficacy consistency evaluation of generic drugs .
-
Under the normalization of alliance procurement, a large number of drugs and consumables will be reduced in price
Time of Update: 2022-04-15
Recently, the Inner Mongolia Autonomous Region Pharmaceutical Procurement Center issued the "Notice on Publicizing the Results of the Proposed Selection of the Third Batch of Centralized Procurement of Drugs in the "Eight Provinces and Two Regions" Inter-Provincial Alliance" .
-
In the context of soil census, the seminar on prevention and detection of heavy metal pollution in agricultural land invites you to have an online dialogue on March 17
Time of Update: 2022-04-15
Symposium on Prevention and Detection of Heavy Metal Pollution in Agricultural Land "Lights Up" Soil census, as an important survey of national conditions and national strength, is inseparable from the support of professional technology and equipment .
-
All localities are vigorously promoting the innovative development of the biomedical industry and striding forward to the "100 billion-level" market!
Time of Update: 2022-04-15
According to the "14th Five-Year Plan for Hefei's Biomedical Industry Development Plan", by 2025, the output value of the city's biomedical industry will exceed 100 billion yuan, and strive to build a national strategic emerging industry cluster .
-
Domestic innovative drugs are on the rise, and innovative achievements such as Fosun and Simcere are accelerating their realization
Time of Update: 2022-04-15
[Pharmaceutical Network Industry News] The "14th Five-Year Plan for the Development of the Pharmaceutical Industry" proposes that during the "14th Five-Year Plan" period, the R&D investment in the entire pharmaceutical industry will increase by more than 10% annually; by 2025, the new sales of innovative products will account for the entire industry.
-
The drug market exceeds 400 million euros, and the original research manufacturers will usher in challengers
Time of Update: 2022-04-15
Today, almost every product market has been firmly controlled by giants in this field, such as Hengrui, Yangzijiang, Bracco, GE, Bayer, and Beilu Pharmaceuticals, all of which have been deeply involved in the contrast agent market for many years .
-
Within 1 day, 3 pharmaceutical companies reported their annual results!
Time of Update: 2022-04-15
The net profit attributable to shareholders of the listed company was 465 million yuan, a year-on-year increase of 10.
28% year-on-year According to the 2021 annual report disclosed by Fosun Pharma, the company achieved operating income of 39.
-
The 3rd QbD Biopharmaceutical Quality Science Conference
Time of Update: 2022-04-15
In this context, how local pharmaceutical companies can go overseas on the premise of adhering to drug quality standards is the focus of this conference .
-
The innovation of local pharmaceutical companies is accelerating, and the situation is becoming more diversified!
Time of Update: 2022-04-15
It is reported that in recent years Bio-Tech, Henlius, and Innovent have all authorized overseas licenses to commercialize new drugs, and have seized both domestic and overseas markets .
-
1957 batches of Chinese herbal decoction pieces were sampled, and 32 batches were non-compliant!
Time of Update: 2022-04-15
In addition, the main problems found in the special sampling inspection of Chinese herbal medicines include: the substitution and doping of counterfeit products; the problem of excessive residues of exogenous harmful substances; the problem of irregular harvesting and processing .
According to the industry, the high-quality development of Chinese herbal decoction pieces has become the general trend .
-
The dry eye drug market of over 40 billion yuan is attracting many pharmaceutical companies to enter the market
Time of Update: 2022-04-15
Among them, the blockbuster ophthalmic product cyclosporine A eye gel has completed a large-scale clinical trial in China, involving 644 patients in 41 centers .
S. Phase II Clinical Trial for Dry Eye On March 23, Dimensional Bio announced that its self-developed innovative drug VVN001 achieved positive results in U.
-
In the annual report dividend season, many pharmaceutical companies distributed cash dividends exceeding 10 yuan for every 10 shares!
Time of Update: 2022-04-15
Among them, many pharmaceutical companies including Yiqiao Shenzhou, Yunnan Baiyao, Livzon Group, Huitai Medical and other pharmaceutical companies distributed cash dividends exceeding 10 yuan per 10 shares .
The 2021 annual report shows that the company achieved a total operating income of 965 million yuan, a year-on-year decrease of 39.
-
"Dry goods" are ready, come to the video conference on April 15th to talk about solid and hazardous waste detection and identification technology
Time of Update: 2022-04-15
Break through the technical blocking points of solid and hazardous waste identification, conduct discussions based on the actual engineering environment, and seek high-quality development of the industry in the future!
-
3 pharmaceutical companies have reviewed 7 varieties, and 2 varieties have been subsidized by 1.5 million yuan each!
Time of Update: 2022-04-15
For example, according to recent news, Nantong Lianya Pharmaceutical, Jiangsu Wangao Pharmaceutical, and Jiangsu Chenpai Pharmaceutical have a total of 7 generic drugs that have passed the consistency evaluation, and 4 of them have received funding of 5 million yuan .
-
Domestic new drugs are "going overseas" constantly, and the value of innovation is accelerating
Time of Update: 2022-04-15
A few days ago, Jinfang Pharmaceutical announced that it has reached a cooperation with SELLAS Life Sciences Group of the United States to license the global development and commercialization rights of the highly selective CDK9 inhibitor GFH009 outside the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan) to SELLAS.
